SCEMBLIX more than doubled the MMR rate at Week 96 vs bosutinib (38% vs 16%; difference: 22% [95% CI, 11-33; P=0.001]).2,3
![heroimage](https://usim.beprod.scemblix-hcp.com/sites/scemblix_hcp_com/files/styles/hero_full_width_width_2560/public/2024-01/untitled_page_1.jpg?itok=EmGD-qfJ)
More patients achieved CCyR at Week 24 with SCEMBLIX (41%) vs bosutinib (24%).2
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) report that switching TKIs due to intolerance may benefit some patients with chronic, low-grade nonhematologic toxicities that are not manageable with supportive care.4
A higher proportion of patients were still on SCEMBLIX at Week 96 (54% vs 20% with bosutinib).3